Late toxicity in head and neck cancer (H&N) patients (pts) treated with hyperfractionated (HF) or accelerated (AC) radiotherapy (RT) and chemotherapy (CT)
Berta Roth, Marcelo Bonomi, C. Pogany, Alejandro Blanco Saborío, V. Cuartero, R. Giglio, E. Mickiewicz(University of Chicago), Leandro Cerchietti(Cornell University), Pablo Menéndez(Parque Tecnológico de la Salud)
Cited by 0
Related Papers
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
|New England Journal of Medicine|2004|1.8k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
Activity of Exemestane in Metastatic Breast Cancer After Failure of Nonsteroidal Aromatase Inhibitors: A Phase II Trial
|Journal of Clinical Oncology|2000|318